Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 679Carcinoma, Non-Small-Cell Lung 324Neoplasms 168Breast Neoplasms 163Urinary Bladder Neoplasms 157Lung Neoplasms 157Neoplasm Metastasis 139Cholangiocarcinoma 112Ovarian Neoplasms 106Biliary Tract Neoplasms 92Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 70Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 60Carcinoma, Transitional Cell 55Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Fallopian Tube Neoplasms 48Lymphoma, Non-Hodgkin 47Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

Carboplatin 8Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Gemcitabine × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡